{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:13:20Z","timestamp":1793506400549,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI183856"],"award-info":[{"award-number":["WI183856"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2015R1C1A1A02036329"],"award-info":[{"award-number":["NRF-2015R1C1A1A02036329"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijantimicag.2016.12.017","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T16:32:53Z","timestamp":1488385973000},"page":"410-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-935X","authenticated-orcid":false,"given":"Young Kyung","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Wook","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-6072","authenticated-orcid":false,"given":"Kyung Sook","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ja","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mda.2003.7","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"49","author":"Foxman","year":"2003","journal-title":"Dis Mon"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Clinical practice. Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0025","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1128\/AAC.00065-13","article-title":"Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010\u20132011","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3349\/ymj.2011.52.5.793","article-title":"Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009","volume":"52","author":"Lee","year":"2011","journal-title":"Yonsei Med J"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2016.12.017_bib0035","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1086\/500663","article-title":"Extended-spectrum \u03b2-lactamases and clinical outcomes: current data","volume":"42","author":"Ramphal","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099101","article-title":"Effects of group 1 versus group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship","volume":"9","author":"Yoon","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0045","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0050","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","article-title":"Extended-spectrum \u03b2-lactamase-producing organisms","volume":"73","author":"Falagas","year":"2009","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0065","article-title":"Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","author":"Lo","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin\u2013tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0080","first-page":"28","article-title":"The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials","volume":"60","author":"Trivedi","year":"2012","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0085","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"69","author":"Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2014.08.018","article-title":"Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"29","author":"Asakura","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11908-007-0075-3","article-title":"Complicated pyelonephritis: unresolved issues","volume":"9","author":"Nicolle","year":"2007","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0100","series-title":"The Sanford guide to antimicrobial therapy 2010","author":"Gilbert","year":"2010"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0105","series-title":"Harrison's principles of internal medicine","author":"Longo","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0115","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3349\/ymj.2010.51.5.768","article-title":"Molecular characteristics of extended spectrum \u03b2-lactamases in Escherichia coli and Klebsiella pneumoniae and the prevalence of qnr in extended spectrum \u03b2-lactamase isolates in a tertiary care hospital in Korea","volume":"51","author":"Kim","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diagmicrobio.2010.02.012","article-title":"High prevalence of extended-spectrum \u03b2-lactamases and plasmid-mediated AmpC \u03b2-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea","volume":"67","author":"Yoo","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12275-011-0491-9","article-title":"Molecular analysis of a prolonged spread of Klebsiella pneumoniae co-producing DHA-1 and SHV-12 \u03b2-lactamases","volume":"49","author":"Yoon","year":"2011","journal-title":"J Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/00365548.2013.775479","article-title":"Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy","volume":"45","author":"Kang","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0140","author":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1469-0691.2007.01864.x","article-title":"Antibiotic policy and prescribing strategies for therapy of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: the role of piperacillin\u2013tazobactam","volume":"14","author":"Peterson","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin\u2013tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0160","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin\u2013tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0165","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin\u2013tazobactam against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1469-0691.2009.02893.x","article-title":"Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin\u2013clavulanate and piperacillin\u2013tazobactam with extended-spectrum \u03b2-lactamase-producing and extended-spectrum \u03b2-lactamase-non-producing Escherichia coli isolates","volume":"16","author":"L\u00f3pez-Cerero","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0175","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/civ007","article-title":"Editorial commentary: bloodstream infection caused by extended-spectrum \u03b2-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?","volume":"60","author":"Perez","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0180","first-page":"167","article-title":"Cefepime versus extended spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"15","author":"Nogueira Kda","year":"2011","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/j.1875-9114.1996.tb02933.x","article-title":"Piperacillin\u2013tazobactam: a new \u03b2-lactam\u2013\u03b2-lactamase inhibitor combination","volume":"16","author":"Daniel","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0190","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijcp.12608","article-title":"Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and antimicrobial activities","volume":"69","author":"Saltoglu","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1345\/aph.1Q473","article-title":"Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum \u03b2-lactamase producing Gram-negative bacteria","volume":"46","author":"Fong","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2016.12.017_bib0200","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/archinte.163.10.1206","article-title":"Acute pyelonephritis adults: prediction of mortality and failure of treatment","volume":"163","author":"Efstathiou","year":"2003","journal-title":"Arch Intern Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791730064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791730064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:26:39Z","timestamp":1750026399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791730064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S092485791730064X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}